![]() ![]() ![]() For road conditions and closures in Texas, visit Drive Texas. Monitor weather and road conditions wherever you are traveling.Report road hazards or anything suspicious to the nearest law enforcement agency.Check your vehicle to make sure it’s properly maintained and always ensure your cargo is secure.On some highways, if you don’t move your vehicle when it’s safe to do so, it’s against the law. Leaving vehicles in a traffic lane increases traffic congestion and leaves those involved with an increased risk of harm or a secondary wreck. If you can Steer It, Clear It: If you are involved in a non-injury crash and your vehicle can be moved, clear the traffic lanes to minimize traffic impact.They can’t maneuver as easily as passenger vehicles and pickup trucks. Don’t cut in front of large trucks, and try not to brake quickly in front of them.Not only is it courteous and avoids impeding traffic, Texas law requires slower traffic to keep to the right and to use the left lane for passing only (when posted). On multi-lane roads, use the left lane for passing only.Don’t drive fatigued - allow plenty of time to reach your destination.Drive defensively, as holiday travel can present additional challenges.If you’re using a navigation device or app, have a passenger operate it, so you can keep your eyes on the road.Texas law prohibits the use of portable wireless devices to read, write or send an electronic message unless the vehicle is stopped. Eliminate distractions while driving, including the use of mobile devices.Slow down, especially in bad weather, heavy traffic, unfamiliar areas or construction zones.Buckle up everyone in the vehicle - it’s the law.12, DPS issued 11,165 warnings and citations for violations of this law. There is no maximum price limit for the instrument however, the maximum award. Show the same courtesy to fellow drivers who are stopped on the side of the road. The High-End Instrumentation (HEI) Grant Program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of high-end, specialized, commercially available instruments or integrated systems. Move Over or Slow Down for police, fire, EMS, Texas Department of Transportation (TxDOT) vehicles and tow trucks stopped on the side of the road with emergency lights activated.Make alternate plans if you are consuming alcohol. Updated safety and efficacy data will be presented. PFS, with a median FU of 7.5 months at the data-cut off, is not estimable at the RP2 dose. With no MTD identified, no IRRs, no significant hematologic toxicity, the RP2 dose is 600 mg. Clinical activity occurred early and was durable. Conclusions: TAK-079 monotherapy is safe, generally well tolerated, and active in patients with RRMM through tested doses. At a median follow-up of 7.5 months, PFS not estimable at the RP2 dose. The clinical benefit rate (minimal response or better) in all 12 patients enrolled at the RP2 dose was 67%. At the RP2 dose, 9 patients received at least 6 cycles of therapy by the data cutoff their ORR was 33%, median duration of response was not estimable. Recommended phase 2 dose (RP2) is to be 600 mg based on no reported DLTs, no MTD identified, and preliminary efficacy (PFS and response ). No drug-related grade 4 AEs, AEs leading to study discontinuation, or on-study deaths reported. Neutropenia was the only drug related grade 3 AEs in 2 or more patients (n = 2) only drug related SAE was 1 Grade 3 diverticulitis. Drug related adverse events (AEs), any grade, occurring in at least 10% of patients were: fatigue (21%), anemia (18%), neutropenia (18%), leukopenia (15%). Three ( 1200 injections administered 2 mild pruritis and 1 moderate swelling. No ≥ Grade 1 early or late systemic infusion reactions (IRR) reported. Median number of prior therapies was 4 (2,12). At study entry, 65% were refractory to both an IMiD and PI 82% refractory to last line of therapy, 21% of patients were previously exposed to at least 1 anti-CD38 monoclonal antibody. Results: 34 patients were enrolled across 5 fixed dose cohorts (TAK-079 45-135-30 mg SC) as of 09 December 2019. SC injection was 2 mL administered in ≤ 1 minute. TAK-079 given as a SC injection weekly for 8 doses, every other week for 8 doses, then monthly until disease progression (PD) or unacceptable toxicity. Patients were refractory or intolerant to at least 1 PI and 1 IMiD. Methods: Pt were eligible after ≥ 3 lines of therapy and previous exposure to immunomodulatory drug (IMiD), proteasome inhibitor (PI), alkylating agent, and corticosteroid prior anti-CD38 therapy allowed. Here we report data from an ongoing dose finding study of TAK-079 monotherapy in patients with RRMM (NCT03439280). Background: TAK-079 is a subcutaneously (SC) administered mAb with multiple modes of action for killing target cells. ![]()
0 Comments
Leave a Reply. |